Organic Process Research & Development
ARTICLE
’
COMPUTATIONAL DETAILS
Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.;
Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson,
G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.;
Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.;
Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.;
Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.;
Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.;
Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski,
V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick,
D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui,
Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.;
Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith,
T.; M. A. Al-Laham, Peng, C. Y.; Nanayakkara, A.; Challacombe, M.;
Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; ,
Pople, J. A.Gaussian 03 , Revision B.05; Gaussian, Inc.; Wallingford, CT;
All geometry optimizations and corresponding frequency
calculations were carried out at the B3LYP/6-31G* level of
theory using the Gaussian 03 suite of programs. Accurate
electronic energies were computed as B3LYP/6-31þG** single
points on the B3LYP/6-31G* geometries. Scaled zero-point
potential energies were used in the calculation of free energies,
using a scaling factor of 0.9806. Solvation energies were
obtained from single-point calculations on the gas-phase opti-
9
10
11
mized geometries, using the IEF-PCM model and the UAKS
set of radii.
’
AUTHOR INFORMATION
2
004.
Corresponding Author
(10) Scott, A. P.; Radom, L. J. Phys. Chem. 1996, 100, 16502–16513.
11) Mennucci, B.; Canc ꢀe s, E.; Tomasi, J. J. Phys. Chem. B 1997,
*
To whom correspondence should be addressed. Email: steven.
raw@astrazeneca.com.
(
101, 10506–10517.
’
ACKNOWLEDGMENT
We are grateful to the AZD0530 Development Manufacturing
team at PR&D (Macclesfield) for their work in the accommoda-
tion of this process. We thank Lyn Powell and Andrew Stark for
many helpful discussions. We thank Peter Crafts for Process
Engineering support and Anna Powell for analytical assis-
tance. Finally, we are indebted to Christine Mee, Safety
Assessment, AstraZeneca, for carrying out the Ames testing
on cyanoaniline 15.
’
REFERENCES
(
1) (a) Ford, J. G.; McCabe, J. F.; O’Kearney-McMullan, A.;
O’Keefe, P.; Pointon, S. M.; Powell, L.; Purdie, M.; Withnall, J. WO/
006/064217, 2006. (b) Ford, J. G.; Pointon, S. M.; Powell, L.; Siedlecki,
2
P. S.; Baum, J.; Chubb, R.; Fieldhouse, R.; Muxworthy, J.; Nivlet, A.;
Stenson, R.; Warwick, E. Org. Process Res. Dev. 2010, 14, 1078–1087. (c)
Ford, J. G.; O’Kearney-McMullan, A.; Pointon, S. M.; Powell, L.;
Siedlecki, P. S.; Purdie, M.; Withnall, J.; O’Keefe, P.; Wood, F. Org.
Process Res. Dev. 2010, 14, 1088–1093.
(2) (a) Hennequin, L. F, A.; Ple, P. WO/2001/94341, 2001. (b)
Hennequin, L. F.; Allen, J.; Breed, J.; Curwen, J.; Fennell, M.; Green,
T. P.; Lambert van der Brempt, C.; Morgentin, R.; Norman, R. A.;
Olivier, A.; Otterbein, L.; Ple, P. A.; Warin, N.; Costello, G. J. Med. Chem.
2
006, 49, 6465–6488.
3) Box, G. E. P.; Hunter, J. S.; Hunter, W. G. Statistics for
(
Experimenters: Design, Discovery and Innovation, 2nd ed.; Wiley Inter-
science: 2005; Chapter 5, pp 173ꢀ222.
(4) Reichardt, C. Solvents and Solvent Effects in Organic Chemistry, 3rd
ed.; Wiley-VCH: 2003; Chapter 4, pp 93ꢀ145.
(
(
5) NIST Chemistry WebBook: http://webbook.nist.gov/chemistry/.
6) (a) M €u ller, L.; Mauthe, R. J.; Riley, C. M.; Andino, M. M.; De
Antonis, D.; Beels, C.; DeGeorge, J.; De Knaep, A. G. M.; Ellison, D.;
Fagerland, J. A.; Frank, R.; Fritschel, B.; Galloway, S.; Harpur, E.;
Humfrey, C. D. N.; Jacks, A. S.; Jagota, N.; Mackinnon, J.; Mohan, G.;
Ness, D. K.; O’Donovan, M. R.; Smith, M. D.; Vudathala, G.; Yotti, L.
Regulatory Toxicology and Pharmacoclogy 2006, 44, 198–211and refer-
ences therein. (b) EMEA Committee for Medicinal Products for Hu-
man Use “Guideline on the Limits of Genotoxic Impurities” EMEA/
CHMP/QWP/251344/2006 (c) EMEA Safety Working Party “Ques-
tion & Answers on the CHMP Guideline on the Limits of Genotoxic
Impurities” EMEA/CHMP/SWP/431994/2007, revision 2.
(7) Maron, D. M.; Ames, B. N. Mutat. Res. 1983, 113, 173–215.
(8) Material gave satisfactory spectroscopic and chromatographic
data upon analysis (see ref 1).
9) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.;
Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A.; , Jr., Vreven, T.;
(
6
92
dx.doi.org/10.1021/op200079g |Org. Process Res. Dev. 2011, 15, 688–692